|
2023-11-21 |
2023-11-17 |
B
Purchase
|
Forbes William P
EVP, Chief Development Officer
Officer
|
25,000
+46.3%
1.09
USD 27,250
|
25,000
+46.3%
|
1.09
|
USD 27,250
|
|
|
2023-11-20 |
2023-11-16 |
B
Purchase
|
Forbes William P
EVP, Chief Development Officer
Officer
|
50,000
+1250.0%
0.94
USD 46,995
|
50,000
+1250.0%
|
0.94
|
USD 46,995
|
|
|
2023-11-17 |
2023-11-16 |
B
Purchase
|
Collard Craig A
Chief Executive Officer
Executive Director
|
150,000
+411.0%
0.92
USD 137,970
|
150,000
+411.0%
|
0.92
|
USD 137,970
|
|
|
2023-11-17 |
2023-11-16 |
B
Purchase
|
Duarte Ira
EVP, Chief Financial Officer
Officer
|
85,000
+inf%
0.89
USD 75,599
|
85,000
+inf%
|
0.89
|
USD 75,599
|
|
|
2023-07-25 |
2023-07-21 |
B
Purchase
|
Morgan Adam
Non-Executive Director
|
2,486,744
+55.3%
1.37
USD 3,406,839
|
2,486,744
+55.3%
|
1.37
|
USD 3,406,839
|
|
|
2022-05-04 |
2022-05-03 |
PS
Planned sale
|
MANHARD KIMBERLY
EVP, Drug Development
Executive Director
|
1,504
-12.2%
4.76
USD 7,154
|
1,504
-12.2%
|
4.76
|
USD 7,154
|
|
|
2021-12-23 |
2021-12-21 |
PS
Planned sale
|
Johnson Craig A
Non-Executive Director
|
250
-8.1%
9.73
USD 2,432
|
250
-8.1%
|
9.73
|
USD 2,432
|
|
|
2021-12-23 |
2021-12-21 |
PS
Planned sale
|
Christian Waage
Non-Executive Director
|
300
-8.6%
9.73
USD 2,920
|
300
-8.6%
|
9.73
|
USD 2,920
|
|
|
2021-06-22 |
2021-06-21 |
PS
Planned sale
|
Christian Waage
Non-Executive Director
|
300
-7.3%
15.20
USD 4,559
|
300
-7.3%
|
15.20
|
USD 4,559
|
|
|
2021-06-22 |
2021-06-21 |
PS
Planned sale
|
Johnson Craig A
Non-Executive Director
|
250
-7.0%
15.20
USD 3,801
|
250
-7.0%
|
15.20
|
USD 3,801
|
|
|
2021-04-16 |
2021-04-15 |
PS
Planned sale
|
Christian Waage
Non-Executive Director
|
300
-6.8%
17.51
USD 5,254
|
300
-6.8%
|
17.51
|
USD 5,254
|
|
|
2021-04-07 |
2021-04-06 |
PS
Planned sale
|
Johnson Craig A
Non-Executive Director
|
250
-6.5%
17.22
USD 4,305
|
250
-6.5%
|
17.22
|
USD 4,305
|
|
|
2021-01-15 |
2021-01-14 |
PS
Planned sale
|
Szekeres David Leslie
EVP, Chief Operating Officer
Officer
|
827
-100.0%
18.09
USD 14,960
|
827
-100.0%
|
18.09
|
USD 14,960
|
|
|
2021-01-08 |
2021-01-08 |
PS
Planned sale
|
Szekeres David Leslie
EVP, Chief Operating Officer
Officer
|
3,571
-100.0%
19.66
USD 70,219
|
3,571
-100.0%
|
19.66
|
USD 70,219
|
|
|
2020-12-23 |
2020-12-22 |
PS
Planned sale
|
MANHARD KIMBERLY
EVP, Drug Development
Executive Director
|
10,000
-100.0%
20.00
USD 200,000
|
10,000
-100.0%
|
20.00
|
USD 200,000
|
|
|
2020-05-01 |
2020-05-01 |
PS
Planned sale
|
MANHARD KIMBERLY
Executive VP, Drug Development
Executive Director
|
1,158
-100.0%
13.97
USD 16,176
|
1,158
-100.0%
|
13.97
|
USD 16,176
|
|
|
2019-12-03 |
2019-11-29 |
PS
Planned sale
|
MANHARD KIMBERLY
Executive VP, Drug Development
Executive Director
|
24,000
-100.0%
26.00
USD 624,000
|
24,000
-100.0%
|
26.00
|
USD 624,000
|
|
|
2019-10-07 |
2019-10-04 |
B
Purchase
|
TANG KEVIN C
|
285,714
+5.2%
17.50
USD 4,999,995
|
285,714
+5.2%
|
17.50
|
USD 4,999,995
|
|
|
2019-10-04 |
2019-10-03 |
B
Purchase
|
Quart Barry D
Chief Executive Officer
Executive Director
|
4,571
+5.1%
17.50
USD 79,993
|
4,571
+5.1%
|
17.50
|
USD 79,993
|
|
|
2019-10-04 |
2019-10-03 |
B
Purchase
|
POYHONEN JOHN
EVP, Chief Commercial Officer
Executive Director
|
5,143
+39.6%
17.50
USD 90,003
|
5,143
+39.6%
|
17.50
|
USD 90,003
|
|
|
2019-05-23 |
2019-05-22 |
B
Purchase
|
POYHONEN JOHN
Non-Executive Director
|
3,000
+30.0%
17.55
USD 52,650
|
3,000
+30.0%
|
17.55
|
USD 52,650
|
|
|
2019-05-16 |
2019-05-15 |
B
Purchase
|
Christian Waage
|
1,400
+inf%
18.04
USD 25,262
|
1,400
+inf%
|
18.04
|
USD 25,262
|
|
|
2019-05-02 |
2019-05-01 |
PS
Planned sale
|
MANHARD KIMBERLY
Executive VP, Drug Development
Officer
|
1,109
-100.0%
18.86
USD 20,918
|
1,109
-100.0%
|
18.86
|
USD 20,918
|
|
|
2018-11-02 |
2018-11-02 |
PS
Planned sale
|
MANHARD KIMBERLY
Executive VP, Drug Development
Officer
|
494
-100.0%
30.62
USD 15,125
|
494
-100.0%
|
30.62
|
USD 15,125
|
|
|
2018-10-02 |
2018-10-01 |
PS
Planned sale
|
MANHARD KIMBERLY
Executive VP, Drug Development
Officer
|
6,000
-100.0%
32.07
USD 192,433
|
6,000
-100.0%
|
32.07
|
USD 192,433
|
|
|
2018-09-12 |
2018-09-12 |
S
Sale
|
TANG KEVIN C
Non-Executive Director
Large shareholder
|
2,695,000
-31.6%
35.75
USD 96,346,250
|
2,695,000
-31.6%
|
35.75
|
USD 96,346,250
|
|
|
2018-07-03 |
2018-07-02 |
PS
Planned sale
|
Rosen Robert
President
Executive Director
|
3,400
-56.3%
38.75
USD 131,765
|
3,400
-56.3%
|
38.75
|
USD 131,765
|
|
|
2018-07-03 |
2018-07-02 |
PS
Planned sale
|
Rosen Robert
President
Executive Director
|
92,131
-93.8%
38.13
USD 3,512,918
|
92,131
-93.8%
|
38.13
|
USD 3,512,918
|
|
|
2018-07-03 |
2018-07-02 |
PS
Planned sale
|
MANHARD KIMBERLY
Executive VP, Drug Development
Officer
|
100
-100.0%
38.85
USD 3,885
|
100
-100.0%
|
38.85
|
USD 3,885
|
|
|
2018-07-03 |
2018-07-02 |
PS
Planned sale
|
MANHARD KIMBERLY
Executive VP, Drug Development
Officer
|
5,900
-98.3%
37.51
USD 221,294
|
5,900
-98.3%
|
37.51
|
USD 221,294
|
|
|
2018-07-03 |
2018-07-02 |
PS
Planned sale
|
HOFFMAN ROBERT
CFO & SVP, Finance
Officer
|
1,060
-45.3%
38.80
USD 41,123
|
1,060
-45.3%
|
38.80
|
USD 41,123
|
|
|
2018-07-03 |
2018-07-02 |
PS
Planned sale
|
HOFFMAN ROBERT
CFO & SVP, Finance
Officer
|
28,940
-92.5%
38.15
USD 1,104,107
|
28,940
-92.5%
|
38.15
|
USD 1,104,107
|
|
|
2018-07-03 |
2018-06-29 |
PS
Planned sale
|
Rosen Robert
President
Executive Director
|
2,112
-44.4%
41.39
USD 87,415
|
2,112
-44.4%
|
41.39
|
USD 87,415
|
|
|
2018-07-03 |
2018-06-29 |
PS
Planned sale
|
Rosen Robert
President
Executive Director
|
51,696
-91.6%
40.17
USD 2,076,597
|
51,696
-91.6%
|
40.17
|
USD 2,076,597
|
|
|
2018-07-03 |
2018-06-29 |
PS
Planned sale
|
Rosen Robert
President
Executive Director
|
75,661
-57.3%
39.14
USD 2,961,122
|
75,661
-57.3%
|
39.14
|
USD 2,961,122
|
|
|
2018-06-22 |
2018-06-21 |
PS
Planned sale
|
Quart Barry D
Chief Executive Officer
Executive Director
|
50,000
-41.8%
39.05
USD 1,952,500
|
50,000
-41.8%
|
39.05
|
USD 1,952,500
|
|
|
2018-04-02 |
2018-03-29 |
B
Purchase
|
TANG KEVIN C
Large shareholder
|
192,308
+2.3%
26.00
USD 5,000,008
|
192,308
+2.3%
|
26.00
|
USD 5,000,008
|
|
|
2018-03-19 |
2018-03-19 |
PS
Planned sale
|
MANHARD KIMBERLY
Executive VP, Drug Development
|
18,000
-100.0%
30.00
USD 540,000
|
18,000
-100.0%
|
30.00
|
USD 540,000
|
|
|
2018-03-19 |
2018-03-19 |
PS
Planned sale
|
Quart Barry D
Chief Executive Officer
Executive Director
|
100,000
-59.5%
29.75
USD 2,975,000
|
100,000
-59.5%
|
29.75
|
USD 2,975,000
|
|
|
2018-03-16 |
2018-03-14 |
PS
Planned sale
|
Quart Barry D
Chief Executive Officer
Executive Director
|
100,000
-59.5%
24.75
USD 2,475,000
|
100,000
-59.5%
|
24.75
|
USD 2,475,000
|
|
|
2018-01-12 |
2018-01-10 |
PS
Planned sale
|
MANHARD KIMBERLY
Executive VP, Drug Development
Officer
|
7,584
-100.0%
20.00
USD 151,680
|
7,584
-100.0%
|
20.00
|
USD 151,680
|
|
|
2017-04-24 |
2017-04-24 |
PS
Planned sale
|
MANHARD KIMBERLY
Executive VP, Drug Development
|
21,542
-100.0%
15.33
USD 330,263
|
21,542
-100.0%
|
15.33
|
USD 330,263
|
|
|
2017-01-23 |
2017-01-19 |
B
Purchase
|
POYHONEN JOHN
|
10,000
+inf%
12.20
USD 122,000
|
10,000
+inf%
|
12.20
|
USD 122,000
|
|
|
2017-01-23 |
2017-01-19 |
B
Purchase
|
TANG KEVIN C
Non-Executive Director
Large shareholder
|
2,459,016
+41.9%
12.20
USD 29,999,995
|
2,459,016
+41.9%
|
12.20
|
USD 29,999,995
|
|
|
2016-08-12 |
2016-08-10 |
PS
Planned sale
|
Rosen Robert
President & CCO
Executive Director
|
12,400
-82.4%
23.89
USD 296,278
|
12,400
-82.4%
|
23.89
|
USD 296,278
|
|
|
2016-08-12 |
2016-08-10 |
PS
Planned sale
|
Rosen Robert
President & CCO
Executive Director
|
87,600
-85.3%
23.21
USD 2,033,616
|
87,600
-85.3%
|
23.21
|
USD 2,033,616
|
|
|
2016-04-21 |
2016-04-21 |
PS
Planned sale
|
Rosen Robert
President
Executive Director
|
19,662
-88.2%
22.15
USD 435,433
|
19,662
-88.2%
|
22.15
|
USD 435,433
|
|
|
2016-04-21 |
2016-04-20 |
PS
Planned sale
|
Rosen Robert
President
Executive Director
|
4,010
-60.3%
22.19
USD 88,967
|
4,010
-60.3%
|
22.19
|
USD 88,967
|
|
|
2016-04-21 |
2016-04-19 |
PS
Planned sale
|
Rosen Robert
President
Executive Director
|
6,230
-70.2%
25.11
USD 156,438
|
6,230
-70.2%
|
25.11
|
USD 156,438
|
|
|
2016-04-21 |
2016-04-19 |
PS
Planned sale
|
Rosen Robert
President
Executive Director
|
32,224
-78.4%
24.49
USD 789,037
|
32,224
-78.4%
|
24.49
|
USD 789,037
|
|
|
2016-04-21 |
2016-04-19 |
PS
Planned sale
|
Rosen Robert
President
Executive Director
|
76,949
-65.2%
23.47
USD 1,805,955
|
76,949
-65.2%
|
23.47
|
USD 1,805,955
|
|
|
2016-04-21 |
2016-04-19 |
PS
Planned sale
|
Rosen Robert
President
Executive Director
|
60,925
-34.0%
22.50
USD 1,370,593
|
60,925
-34.0%
|
22.50
|
USD 1,370,593
|
|
|
2015-06-12 |
2015-06-10 |
B
Purchase
|
TANG KEVIN C
Non-Executive Director
Large shareholder
|
121,212
+2.6%
24.75
USD 2,999,997
|
121,212
+2.6%
|
24.75
|
USD 2,999,997
|
|
|
2015-06-03 |
2015-06-02 |
S
Sale
|
MANHARD KIMBERLY
Non-Executive Director
|
10,500
-100.0%
23.58
USD 247,590
|
10,500
-100.0%
|
23.58
|
USD 247,590
|
|
|
2015-06-02 |
2015-06-02 |
B
Purchase
|
TANG KEVIN C
Non-Executive Director
Large shareholder
|
32,395
+0.7%
23.84
USD 772,294
|
32,395
+0.7%
|
23.84
|
USD 772,294
|
|
|
2015-06-03 |
2015-06-01 |
S
Sale
|
MANHARD KIMBERLY
Non-Executive Director
|
2,708
-100.0%
21.17
USD 57,328
|
2,708
-100.0%
|
21.17
|
USD 57,328
|
|
|
2015-06-02 |
2015-06-01 |
B
Purchase
|
TANG KEVIN C
Non-Executive Director
Large shareholder
|
2,380
+0.1%
19.30
USD 45,934
|
2,380
+0.1%
|
19.30
|
USD 45,934
|
|
|
2015-06-02 |
2015-05-29 |
B
Purchase
|
TANG KEVIN C
Non-Executive Director
Large shareholder
|
115,225
+2.5%
19.74
USD 2,274,058
|
115,225
+2.5%
|
19.74
|
USD 2,274,058
|
|
|
2015-03-09 |
2015-03-05 |
PS
Planned sale
|
Marshall Paul
SVP, Technical Operations
Officer
|
20,000
-100.0%
15.40
USD 308,000
|
20,000
-100.0%
|
15.40
|
USD 308,000
|
|
|
2015-03-09 |
2015-03-05 |
PS
Planned sale
|
Marshall Paul
SVP, Technical Operations
Officer
|
50,000
-71.4%
14.40
USD 720,000
|
50,000
-71.4%
|
14.40
|
USD 720,000
|
|
|
2014-06-27 |
2014-06-25 |
B
Purchase
|
TANG KEVIN C
Non-Executive Director
Large shareholder
|
510,638
+12.5%
11.75
USD 5,999,997
|
510,638
+12.5%
|
11.75
|
USD 5,999,997
|
|
|
2014-06-26 |
2014-06-25 |
B
Purchase
|
Quart Barry D
Chief Executive Officer
Executive Director
|
10,000
+19.3%
11.75
USD 117,500
|
10,000
+19.3%
|
11.75
|
USD 117,500
|
|
|
2013-11-21 |
2013-11-20 |
B
Purchase
|
Quart Barry D
Chief Executive Officer
Executive Director
|
1,000,000
+2695.4%
0.40
USD 400,000
|
1,000,000
+2695.4%
|
0.40
|
USD 400,000
|
|
|
2012-09-12 |
2012-07-25 |
B
Purchase
|
SPCH, LLLP
Large shareholder
|
38,095,238
+inf%
0.53
USD 20,000,000
|
38,095,238
+inf%
|
0.53
|
USD 20,000,000
|
|
|
2009-10-21 |
2009-10-19 |
B
Purchase
|
TANG KEVIN C
Non-Executive Director
Large shareholder
|
2,443,181
+30.6%
0.88
USD 2,149,999
|
2,443,181
+30.6%
|
0.88
|
USD 2,149,999
|
|
|
2009-01-05 |
2008-12-31 |
B
Purchase
|
TANG KEVIN C
Large shareholder
|
175,000
+2.2%
0.42
USD 72,625
|
175,000
+2.2%
|
0.42
|
USD 72,625
|
|
|
2008-12-22 |
2008-12-18 |
B
Purchase
|
TANG KEVIN C
Large shareholder
|
415,300
+5.6%
0.48
USD 200,673
|
415,300
+5.6%
|
0.48
|
USD 200,673
|
|
|
2008-11-17 |
2008-11-13 |
B
Purchase
|
TANG KEVIN C
Large shareholder
|
775,032
+11.7%
0.48
USD 372,015
|
775,032
+11.7%
|
0.48
|
USD 372,015
|
|
|
2008-11-17 |
2008-11-13 |
B
Purchase
|
TANG KEVIN C
Large shareholder
|
66,000
+1.0%
0.50
USD 32,710
|
66,000
+1.0%
|
0.50
|
USD 32,710
|
|
|
2008-11-12 |
2008-11-10 |
S
Sale
|
ROSENBLATT TOBY
Non-Executive Director
|
40,000
-100.0%
0.51
USD 20,524
|
40,000
-100.0%
|
0.51
|
USD 20,524
|
|
|
2008-11-12 |
2008-11-10 |
S
Sale
|
ROSENBLATT TOBY
Non-Executive Director
|
6,881
-18.5%
0.51
USD 3,531
|
6,881
-18.5%
|
0.51
|
USD 3,531
|
|
|
2008-11-04 |
2008-10-31 |
B
Purchase
|
TANG KEVIN C
Large shareholder
|
336,300
+5.4%
0.61
USD 204,067
|
336,300
+5.4%
|
0.61
|
USD 204,067
|
|
|
2008-10-14 |
2008-10-10 |
B
Purchase
|
TANG KEVIN C
Large shareholder
|
870,000
+16.2%
0.74
USD 647,019
|
870,000
+16.2%
|
0.74
|
USD 647,019
|
|
|
2008-10-02 |
2008-09-30 |
B
Purchase
|
TANG KEVIN C
Large shareholder
|
650,000
+13.8%
0.97
USD 627,900
|
650,000
+13.8%
|
0.97
|
USD 627,900
|
|
|
2008-08-06 |
2008-08-01 |
B
Purchase
|
PRENTKI RONALD J
President & CEO
Executive Director
|
1,200
+181.8%
1.42
USD 1,704
|
1,200
+181.8%
|
1.42
|
USD 1,704
|
|
